{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:54:41Z","timestamp":1790319281703,"version":"4.1.0"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,24]]},"DOI":"10.1093\/ecco-jcc\/jjx128","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T16:42:18Z","timestamp":1505407338000},"page":"188-196","source":"Crossref","is-referenced-by-count":28,"title":["Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating \u03b27+ T Cells in Crohn\u2019s Disease: Report of the TOSCA Study"],"prefix":"10.1093","volume":"12","author":[{"given":"Geert","family":"D\u2019Haens","sequence":"first","affiliation":[{"name":"Academic Medical Center, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Vermeire","sequence":"additional","affiliation":[{"name":"Leuven University Hospital, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Vogelsang","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Allez","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Universit\u00e9 Paris Diderot, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Desreumaux","sequence":"additional","affiliation":[{"name":"University of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Van Gossum","sequence":"additional","affiliation":[{"name":"Erasme Hospital, Free University of Brussels, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J","family":"Sandborn","sequence":"additional","affiliation":[{"name":"University of California San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Baumgart","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Medical School, Humboldt-University of Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M","family":"Ransohoff","sequence":"additional","affiliation":[{"name":"Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail M","family":"Comer","sequence":"additional","affiliation":[{"name":"Kimberton Drug Development Consulting, Phoenixville, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cataldi","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Cheng","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Clare","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J","family":"Gorelick","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamarie","family":"Kaminski","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunday","family":"Rivers","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew O","family":"Sikpi","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Hassan-Zahraee","sequence":"additional","affiliation":[{"name":"Pfizer, Cambridge, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"},{"name":"McMaster University, Hamilton, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Stuve","sequence":"additional","affiliation":[{"name":"Neurology Section, VA North Texas Health Care System, Dallas, TX, USA"},{"name":"Southwestern Medical Center, University of Texas, Dallas, TX, USA"},{"name":"Department of Neurology, Klinikum rechts der Isar, Technische Universit\u00e4t M\u00fcnchen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,16]]},"reference":[{"key":"key\n\t\t\t\t20180315032337_CIT0001","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nri1130","article-title":"Three or more routes for leukocyte migration into the central nervous system","volume":"3","author":"Ransohoff","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t20180315032337_CIT0002","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/ni.f.208","article-title":"Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking","volume":"9","author":"Sigmundsdottir","year":"2008","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t20180315032337_CIT0003","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","article-title":"A novel targeted T cell modulator, efalizumab, for plaque psoriasis","volume":"349","author":"Lebwohl","year":"2003","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032337_CIT0004","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032337_CIT0005","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032337_CIT0006","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000150537","article-title":"Progressive multifocal leukoencephalopathy: molecular biology, pathogenesis and clinical impact","volume":"40","author":"Weber","year":"1997","journal-title":"Intervirology"},{"key":"key\n\t\t\t\t20180315032337_CIT0007","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nri3265","article-title":"The anatomical and cellular basis of immune surveillance in the central nervous system","volume":"12","author":"Ransohoff","year":"2012","journal-title":"Nat Rev Immunol"},{"key":"key\n\t\t\t\t20180315032337_CIT0008","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","article-title":"Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Dong-Si","year":"2015","journal-title":"J Neurovirol"},{"key":"key\n\t\t\t\t20180315032337_CIT0009","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports [RADAR] Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t20180315032337_CIT0010","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032337_CIT0011","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"St\u00fcve","year":"2006","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180315032337_CIT0012","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coph.2015.11.007","article-title":"Integrins and adhesion molecules as targets to treat inflammatory bowel disease","volume":"25","author":"Bravat\u00e0","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"key\n\t\t\t\t20180315032337_CIT0013","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohn\u2019s disease","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315032337_CIT0014","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/ibd.20453","article-title":"Lymphocyte homing and its role in the pathogenesis of IBD","volume":"14","author":"Eksteen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"key\n\t\t\t\t20180315032337_CIT0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10787-011-0104-6","article-title":"Targeting leukocyte migration and adhesion in Crohn\u2019s disease and ulcerative colitis","volume":"20","author":"Thomas","year":"2012","journal-title":"Inflammopharmacology"},{"key":"key\n\t\t\t\t20180315032337_CIT0016","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1177\/1756283X10373176","article-title":"Anti-adhesion molecule therapy for inflammatory bowel disease","volume":"3","author":"Ghosh","year":"2010","journal-title":"Ther Adv Gastroenterol"},{"key":"key\n\t\t\t\t20180315032337_CIT0017","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180315032337_CIT0018","first-page":"1819","article-title":"ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro","volume":"148","author":"Steffen","year":"1996","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180315032337_CIT0019","doi-asserted-by":"crossref","first-page":"556","DOI":"10.2353\/ajpath.2010.090437","article-title":"CNS elevation of vascular and not mucosal addressin cell adhesion molecules in patients with multiple sclerosis","volume":"176","author":"Allavena","year":"2010","journal-title":"Am J Pathol"},{"key":"key\n\t\t\t\t20180315032337_CIT0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1476-5381.2009.00137.x","article-title":"Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody","volume":"157","author":"Pullen","year":"2009","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20180315032337_CIT0021","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/gut.2010.226548","article-title":"The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study","volume":"60","author":"Vermeire","year":"2011","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032337_CIT0022","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(80)92767-1","article-title":"A simple index of Crohn\u2019s-disease activity","volume":"1","author":"Harvey","year":"1980","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180315032337_CIT0023","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cyto.b.20603","article-title":"Flow cytometric characterization of cerebrospinal fluid cells","volume":"80","author":"de Graaf","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"key\n\t\t\t\t20180315032337_CIT0024","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/cyto.b.20542","article-title":"Central memory CD4+ T cells dominate the normal cerebrospinal fluid","volume":"80","author":"de Graaf","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"key":"key\n\t\t\t\t20180315032337_CIT0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jim.2004.09.013","article-title":"Evaluation of leukocyte stabilisation in TransFix-treated blood samples by flow cytometry and transmission electron microscopy","volume":"295","author":"Canonico","year":"2004","journal-title":"J Immunol Methods"},{"key":"key\n\t\t\t\t20180315032337_CIT0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/vim.2009.0027","article-title":"Evaluation of the blood stabilizers TransFix and Cyto-Chex BCT for low-cost CD4 T cell methodologies","volume":"22","author":"Plate","year":"2009","journal-title":"Viral Immunol"},{"key":"key\n\t\t\t\t20180315032337_CIT0027","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1136\/gutjnl-2015-310022","article-title":"Differential effects of \u03b14\u03b27 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo","volume":"65","author":"Fischer","year":"2016","journal-title":"Gut"},{"key":"key\n\t\t\t\t20180315032337_CIT0028","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180315032337_CIT0029","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/ana.24051","article-title":"Progressive multifocal leukoencephalopathy after natalizumab discontinuation","volume":"75","author":"Fine","year":"2014","journal-title":"Ann Neurol"},{"key":"key\n\t\t\t\t20180315032337_CIT0030","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1128\/JVI.02191-07","article-title":"Regulation of immune response and inflammatory reactions against viral infection by VCAM-1","volume":"82","author":"Ou","year":"2008","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180315032337_CIT0031","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1046\/j.1440-1711.2000.00947.x","article-title":"Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression","volume":"78","author":"Kanwar","year":"2000","journal-title":"Immunol Cell Biol"},{"key":"key\n\t\t\t\t20180315032337_CIT0032","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/eji.201040912","article-title":"TET inducible expression of the \u03b14\u03b27-integrin ligand MAdCAM-1 on the blood-brain barrier does not influence the immunopathogenesis of experimental autoimmune encephalomyelitis","volume":"41","author":"D\u00f6ring","year":"2011","journal-title":"Eur J Immunol"},{"key":"key\n\t\t\t\t20180315032337_CIT0033","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032337_CIT0034","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180315032337_CIT0035","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","article-title":"Vedolizumab, a monoclonal antibody to the gut homing \u03b14\u03b27 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype","volume":"264","author":"Milch","year":"2013","journal-title":"J Neuroimmunol"},{"key":"key\n\t\t\t\t20180315032337_CIT0036","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.4049\/jimmunol.1202490","article-title":"Antagonizing the \u03b14\u03b21 integrin, but not \u03b14\u03b27, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis","volume":"190","author":"Haanstra","year":"2013","journal-title":"J Immunol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/12\/2\/188\/24365548\/jjx128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,15]],"date-time":"2018-03-15T03:24:03Z","timestamp":1521084243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/12\/2\/188\/4159446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,16]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,9,16]]},"published-print":{"date-parts":[[2018,1,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjx128","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,2]]},"published":{"date-parts":[[2017,9,16]]}}}